These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 37146911)
1. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis. Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911 [TBL] [Abstract][Full Text] [Related]
2. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913 [TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
4. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569 [TBL] [Abstract][Full Text] [Related]
6. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy. Edin S; Gylling B; Li X; Stenberg Å; Löfgren-Burström A; Zingmark C; van Guelpen B; Ljuslinder I; Ling A; Palmqvist R Br J Cancer; 2024 Jan; 130(1):143-150. PubMed ID: 38040818 [TBL] [Abstract][Full Text] [Related]
7. Genomic and prognostic heterogeneity among RAS/BRAF Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154 [TBL] [Abstract][Full Text] [Related]
8. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368 [TBL] [Abstract][Full Text] [Related]
9. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related]
10. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
11. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review. Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887 [TBL] [Abstract][Full Text] [Related]
12. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Lin PS; Semrad TJ Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315 [TBL] [Abstract][Full Text] [Related]
13. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q Front Immunol; 2022; 13():974793. PubMed ID: 36700211 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459 [TBL] [Abstract][Full Text] [Related]
16. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553 [TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994 [TBL] [Abstract][Full Text] [Related]
19. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779 [TBL] [Abstract][Full Text] [Related]
20. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]